These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 27622299)
1. Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Sparrow E; Friede M; Sheikh M; Torvaldsen S; Newall AT Vaccine; 2016 Oct; 34(45):5442-5448. PubMed ID: 27622299 [TBL] [Abstract][Full Text] [Related]
2. Passive immunization with influenza haemagglutinin specific monoclonal antibodies. Rudraraju R; Subbarao K Hum Vaccin Immunother; 2018; 14(11):2728-2736. PubMed ID: 29985756 [TBL] [Abstract][Full Text] [Related]
3. Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. Clementi N; Criscuolo E; Castelli M; Clementi M New Microbiol; 2012 Oct; 35(4):399-406. PubMed ID: 23109007 [TBL] [Abstract][Full Text] [Related]
4. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors. Morgan SB; Holzer B; Hemmink JD; Salguero FJ; Schwartz JC; Agatic G; Cameroni E; Guarino B; Porter E; Rijal P; Townsend A; Charleston B; Corti D; Tchilian E Front Immunol; 2018; 9():865. PubMed ID: 29740451 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195 [TBL] [Abstract][Full Text] [Related]
7. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain. Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330 [TBL] [Abstract][Full Text] [Related]
8. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice. Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088 [TBL] [Abstract][Full Text] [Related]
9. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655 [TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibodies broadly neutralizing against influenza B virus. Yasugi M; Kubota-Koketsu R; Yamashita A; Kawashita N; Du A; Sasaki T; Nishimura M; Misaki R; Kuhara M; Boonsathorn N; Fujiyama K; Okuno Y; Nakaya T; Ikuta K PLoS Pathog; 2013 Feb; 9(2):e1003150. PubMed ID: 23408886 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity. Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J Front Immunol; 2018; 9():3103. PubMed ID: 30761157 [TBL] [Abstract][Full Text] [Related]
12. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Sparrow E; Wood JG; Chadwick C; Newall AT; Torvaldsen S; Moen A; Torelli G Vaccine; 2021 Jan; 39(3):512-520. PubMed ID: 33341308 [TBL] [Abstract][Full Text] [Related]
13. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. Settembre EC; Dormitzer PR; Rappuoli R J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014 [TBL] [Abstract][Full Text] [Related]
14. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R mBio; 2017 Sep; 8(5):. PubMed ID: 28928215 [TBL] [Abstract][Full Text] [Related]
15. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Sakabe S; Iwatsuki-Horimoto K; Horimoto T; Nidom CA; Le Mt; Takano R; Kubota-Koketsu R; Okuno Y; Ozawa M; Kawaoka Y Antiviral Res; 2010 Dec; 88(3):249-55. PubMed ID: 20849879 [TBL] [Abstract][Full Text] [Related]
16. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
17. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Cho A; Wrammert J Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684 [TBL] [Abstract][Full Text] [Related]